What is the Gufic Biosciences PE ratio today?
Gufic Biosciences' PE ratio is 57.2 at the 29 October 2026 close (₹418.80 a share): a market capitalisation of ₹4,200 crore divided by consolidated net profit of ₹73.5 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹64.2 crore) it is 65.4.
What is the Gufic Biosciences debt to equity ratio?
Gufic Biosciences' debt-to-equity ratio was 0.58 on 31 March 2026: borrowings of ₹385 crore against total equity of ₹665 crore. A year earlier, on 31 March 2025, it was 0.52.
What is the Gufic Biosciences net worth?
Gufic Biosciences' net worth — shareholders' equity in its consolidated balance sheet — was ₹665 crore on 31 March 2026, up 10.6% from ₹601 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹4,200 crore at the 29 October 2026 close.
What is the Gufic Biosciences PB ratio (price to book value)?
Gufic Biosciences' price-to-book (PB) ratio is 6.32 at the 29 October 2026 close: a market capitalisation of ₹4,200 crore divided by shareholders' equity (book value) of ₹665 crore on 31 March 2026. That is a book value of ₹66.31 per share against a share price of ₹418.80.
What is the Gufic Biosciences ROE and ROCE?
In FY26, Gufic Biosciences' return on equity (ROE) was 10.1% and its return on capital employed (ROCE) was 15.0%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 12.3% and ROCE 15.1%.
What is the Gufic Biosciences book value per share?
Gufic Biosciences' book value per share was ₹66.31 on 31 March 2026: shareholders' equity of ₹665 crore divided by the 10.03 crore shares in issue, up 10.6% from ₹59.94 a year earlier. The share price at the 29 October 2026 close was ₹418.80.
What is the Gufic Biosciences market cap?
Gufic Biosciences' market capitalisation was ₹4,200 crore at the 29 October 2026 close: 10.03 crore shares at ₹418.80 each.
What is the Gufic Biosciences EPS?
Gufic Biosciences' basic earnings per share (EPS) were ₹6.40 in FY26, against ₹6.95 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹7.32.
What is the Gufic Biosciences dividend in 2026 and its record date?
In 2026, Gufic Biosciences has declared one dividend: ₹0.10 with record date 28 August 2026.
Is Gufic Biosciences debt free?
No. Gufic Biosciences had borrowings of ₹385 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.58. Its cash and current investments were ₹76.2 crore, so its net debt was ₹309 crore.
What is the Gufic Biosciences dividend yield?
Gufic Biosciences' dividend yield is 0.02% at the 29 October 2026 close: dividends of ₹0.10 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹418.80. They were ₹0.10 on 28 August 2026.
When are the Gufic Biosciences next results?
Gufic Biosciences has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.
What is the Gufic Biosciences promoter holding?
Promoters held 72.50% of Gufic Biosciences on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Gufic Biosciences free cash flow?
In FY26, Gufic Biosciences generated ₹45 crore of cash from operations and spent ₹31.2 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹13.8 crore. In FY25 it was ₹47 crore.
What is the Gufic Biosciences revenue and profit in FY26?
In FY26 (April 2025–March 2026), Gufic Biosciences' consolidated net profit was ₹64.2 crore, down 7.8% from ₹69.6 crore in FY25, on revenue from operations of ₹944 crore (up 15.2%).
What is the Gufic Biosciences shareholding pattern?
On 30 September 2026, Gufic Biosciences' shares were held by promoters 72.50%, foreign portfolio investors (FII/FPI) 0.45%, domestic institutions (DII) 3.38% (including mutual funds at 3.03%) and retail and other non-institutional investors 23.67%. Over the year, FII holding was up 0.11 percentage points from 0.34% and DII holding was down 0.27 percentage points from 3.65%.
What are the Gufic Biosciences latest quarterly results?
Gufic Biosciences' latest results are for Q1 FY27 (April–June 2026), filed on 14 August 2026: consolidated net profit ₹22.3 crore, up 70.7% from ₹13.1 crore in Q1 FY26; revenue from operations ₹261 crore, up 16.6% year on year.
How does the Gufic Biosciences PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Gufic Biosciences' PE ratio is 65.4, the second highest of the four: RPG Life Sciences 43.1, Unichem Laboratories 14.1 and Gujarat Themis Biosyn 87.7, a peer average of 48.3. Each is the company's market capitalisation at that price divided by its FY26 net profit.
How does Gufic Biosciences compare with its peers?
On FY26 consolidated figures, against RPG Life Sciences, Unichem Laboratories and Gujarat Themis Biosyn: Gufic Biosciences' operating margin of 12.8% is the third highest of the four (RPG Life Sciences 17.8%, Unichem Laboratories 2.7%, Gujarat Themis Biosyn 37.8%; peer average 19.4%); its return on equity of 10.1% is the third highest of the four (RPG Life Sciences 20.3%, Unichem Laboratories 9.8%, Gujarat Themis Biosyn 17.4%; peer average 15.8%).
Gufic Biosciences vs RPG Life Sciences: how do they compare?
In FY26, Gufic Biosciences earned net profit of ₹64.2 crore on revenue of ₹944 crore, against ₹115 crore on ₹708 crore for RPG Life Sciences. Gufic Biosciences' operating margin was 12.8% (RPG Life Sciences 17.8%) and its return on equity 10.1% (RPG Life Sciences 20.3%). At the 29 October 2026 close, Gufic Biosciences' market capitalisation was ₹4,200 crore against ₹4,968 crore for RPG Life Sciences, and its PE ratio on FY26 profit 65.4 against 43.1.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
